Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease but occurs in people who drink little or no alcohol, and is a highly progressed form of non-alcoholic fatty liver disease (NAFLD). NASH is becoming increasingly common with the alarming epidemic of obesity and carries the risk for more aggressive liver diseases such as cirrhosis, liver failure, and in some rare instances, hepatocellular cancer.
Therapeutic options for NASH are currently very limited, with Vitamin E being the standard of care for patients. This leaves significant unmet need for the disease and, coupled with high disease prevalence in developed countries, results in enticing opportunities for drug developers. As such, there is a very active pipeline for NASH, and many new products are expected to launch over the next 10 years. However, there is still uncertainty over how the NASH treatment landscape will develop as these new products launch.
Key Questions Answered
The NASH market is poised to undergo rapid expansion during the forecast period and beyond. What are the main drivers of this expansion?
What are the main unmet needs in NASH? Will the drugs under development fulfil these needs?
Which patients are the most likely to receive drug treatment for NASH during the forecast period, and which patients are unlikely to be reimbursed?

Scope

GlobalData’s Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026 consists of a slide deck detailing key market-impacting events that have occurred since GlobalData’s previous NASH report publication, along with an updated Excel-based forecasting model which reflects the projected influence of these events on the future NASH market.

The Key Events covered in this NASH Dynamic Market Forecast include:

• Increased Understanding of Potential Treatment Algorithms for NASH Patients With Cirrhosis.

• First Publication of Efficacy Data for Several Phase II NASH Drugs.

• Development of Combination Therapies for NASH.

• Publication of New Phase II Efficacy Data Shifts Competitive Landscape for NASH Pipeline.

Components of the slide deck include:

• Timeline of market-impacting events

• Key clinical trial landscape updates

• Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective

• Overview of updates to the forecast model based on anticipated future impact of events

• Forward-looking events calendar listing expected key updates to the NASH competitive space through September 2019

Other events included in the analysis include:

• Regulatory filings

• Approval decisions

• Pricing changes

• Patent litigation

• Clinical trial data announcements

• Clinical trial failures

• Clinical trial timeline updates

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global NASH therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NASH therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Allergan
Cirius Therapeutics
Conatus Pharma
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead Sciences
Immuron
Intercept Pharmaceuticals
Inventiva
Madrigal Pharmaceuticals
Mitsubishi Tanabe
NGM Bio
Novartis
Novo Nordisk
Viking Therapeutics

Table of Contents

Table of Contents (PowerPoint Deck)

1 Dynamic Market Forecast Overview

1.1 Related Reports

1.2 Upcoming Related Reports

2 Executive Summary

2.1 Key Updates to NASH Market Dynamics

2.2 Key Events in Update

2.3 Clinical Trial Landscape Updates

2.4 Competitive Assessment of Late-Stage Pipeline

2.5 Market Insight on Key Events

3 Event 1: Increased Understanding of Potential Treatment Algorithms for NASH Patients With Cirrhosis

3.1 Key Event Updates

3.2 Competitive Landscape of Drugs Targeting NASH F4 Patients

3.3 New Pricing Model to Differentiate Between Patient Segments

3.4 Increased competition in the NASH Pipeline Within the F4 Patient Segment

3.5 What Do Physicians Think?

3.6 Summary

3.7 Sources

4 Event 2: First Publication of Efficacy Data for Certain Phase II NASH Drugs

4.1 Key Event Updates

4.2 Competitive Landscape of New Drugs added to Forecast

4.3 Four Phase II Drugs Shown to Lower Liver Fat Content

4.4 Summary

4.5 Sources

5 Event 3: Combination Therapies for NASH

5.1 Key Event Updates

5.2 Gilead Shifts NASH Strategy Towards Combination Therapies

5.3 What Do Physicians Think

5.4 Summary

5.5 Sources

6 Event 4: Publication of New Phase II Efficacy Data Shifts Competitive Landscape for NASH Pipeline

6.1 Key Event Updates

6.2 Cenicriviroc and IMM-124E Supported by More Positive Phase II Data

6.3 Poor Phase IIb Efficacy results for Galmed’s Aramchol

6.4 Competitive Landscape of Drugs With Recently Published Efficacy Data

6.5 Summary

6.6 Sources

7 Events Calendar

7.1 Key Events Expected to Occur in October 2018 – September 2019

8 Appendix

8.1 Methodology

8.2 Primary Research

8.3 About the Authors

8.4 About GlobalData

8.5 Contact Us

8.6 Disclaimer

Frequently asked questions

Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026 thematic reports
Currency USD
$8,495

Can be used by individual purchaser only

$25,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026 in real time.

  • Access a live Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.